South Africa reports more than 55,000 starts in its long-acting HIV prevention programme
September figures from the health department cover an initial phase across 360 public facilities. A new prevention option is now available through participating clinics.

South Africa's health department reported on September 8 that 55,123 people had started receiving lenacapavir for HIV prevention by the previous day. The initial rollout covered 360 public facilities in 24 districts across six provinces. The government launched the programme in June in Secunda, Mpumalanga.
Lenacapavir is a long-acting preventive medicine. It offers people at risk another option alongside existing forms of pre-exposure prophylaxis, commonly called PrEP. The initial figures describe enrolment in a public programme, not evidence of how many infections it has prevented. That takes follow-up and monitoring over a longer period.
The health department reported that Gauteng recorded the largest number of starts and that women represented most early recipients. That pattern reflects who the first stage of the programme reached, not necessarily how demand is distributed nationwide. UNAIDS welcomed the launch while emphasizing that access to long-acting prevention should sit alongside broader sexual and reproductive health services and community programmes.
Early distribution also brings practical questions. A product can be approved and useful without being available at every clinic. The next programme indicators include geographic expansion, continuity of supply and whether people who start prevention can stay in care. The September totals are a dated snapshot of reach, not a claim about present-day availability in any individual facility.